Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Bel-sar's Promise | Explore bel-sar's potential in treating choroidal melanoma and bladder cancer, with 80% of patients maintaining tumor control in Phase 2 trials |
Clinical Progress | Delve into Aura's ongoing Phase 3 CoMpass trial for choroidal melanoma and planned Phase 2 trials for choroidal metastasis and ocular surface cancers |
Market Opportunities | Discover Aura's estimated addressable market of 8,000 early-stage choroidal melanoma patients annually in the U.S. and EU, with potential peak sales of $1.5 billion |
Financial Outlook | Learn about Aura's strong financial position with $187 million in cash, providing runway into 2026, and a $23 price target from JMP Securities |
Metrics to compare | AURA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAURAPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.5x | −3.6x | −0.5x | |
PEG Ratio | 1.55 | 0.01 | 0.00 | |
Price/Book | 3.3x | 2.8x | 2.6x | |
Price / LTM Sales | - | 10.0x | 3.3x | |
Upside (Analyst Target) | 231.8% | 183.7% | 43.5% | |
Fair Value Upside | Unlock | 0.5% | 6.9% | Unlock |